Dengue shock syndrome is the most severe form of Dengue that can be fatal. Nonresponders to standard therapy need intensive care. This paper outlines the clinical features, complications, and outcomes of Dengue Shock Syndrome not responding to standard therapies and needing supportive care in a tertiary referral intensive care unit of a developing country. Nearly one-third die within 3 days of admission to ICU. Peritoneal dialysis predicts the worst outcomes. 1. Introduction Dengue is an important arthropod-borne viral disease of humans [1]. Its presentation varies from a mild viral syndrome to hemorrhagic fever and severe shock. Its severe forms (hemorrhagic fever and shock syndrome) may lead to multiorgan involvement and death. Dengue Shock Syndrome (DSS) is characterized by a massive increase in systemic capillary permeability with consequent hypovolemia [2]. The mortality rate in Dengue Shock Syndrome ranges from 6 to 30 percent, most commonly reported in children. Fluid resuscitation is critical with added support for failing organs [3]. In the recent past, Sri Lanka has experienced a surge of the disease reaching epidemic proportions associated with a probable change in the virus strain to a more virulent form [4, 5]. In this context we have also noted a rise in the number of cases with severe forms of the disease needing intensive care. The Peradeniya ICU is a tertiary referral centre and it attracts a large number of above patients with Dengue Shock Syndrome in the region who do not respond to standard therapy with intravenous fluids, antibiotics, and supportive care including inotropes. 2. Methods We collected demographic data of all patients referred for intensive care between January 2009 and June 2010 (18 months) and analyzed their outcomes in relation to the complications of DSS that ensued during their ICU stay and the therapies given. The diagnosis of Dengue has been established upon clinical grounds (WHO guidelines 2009) and treated accordingly by the referring physicians before admission to the ICU. On admission to ICU, all have had fever, vomiting 78%, abdominal pain 21%, cough 5%, and body ache among 3% of cases. Eleven patients have had serological tests and Dengue IgM was found to be positive amongst 72% and IgG in 50% of the tested. They all have had intravenous fluid therapies and antibiotics. During the course of therapy in ICU, 43.6% of cases received fresh frozen plasma, 21.8% cryoprecipitate, 32.7% blood, and 56.4% platelet transfusions. Furthermore, 36.4% of cases were mechanically ventilated for multiple reasons such as
References
[1]
D. J. Gubler, “Dengue and dengue hemorrhagic fever,” Clinical Microbiology Reviews, vol. 11, no. 3, pp. 480–496, 1998.
[2]
T. N. Ngo, C. X. T. Phuong, R. Kneen et al., “Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour,” Clinical Infectious Diseases, vol. 32, no. 2, pp. 204–213, 2001.
[3]
S. Ranjit and N. Kissoon, “Dengue hemorrhagic fever and shock syndromes,” Pediatric Critical Care Medicine, vol. 12, no. 1, pp. 90–100, 2010.
[4]
G. N. Malavige, V. G. N. S. Velathanthiri, E. S. Wijewickrama et al., “Patterns of disease among adults hospitalized with dengue infections,” QJM, vol. 99, no. 5, pp. 299–305, 2006.
[5]
S. A. M. Kularatne, I. B. Gawarammana, and P. R. V. Kumarasiri, “Epidemiology, clinical features, laboratory investigations and early diagnosis of dengue fever in adults: a descriptive study in Sri Lanka,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 36, no. 3, pp. 686–692, 2005.
[6]
S. Singhi, N. Kissoon, and A. Bansal, “Dengue and dengue hemorrhagic fever: management issues in an intensive care unit,” Jornal de Pediatria, vol. 83, no. 2, supplement, pp. S22–S35, 2007.
[7]
T. K. Samsi, H. Wulur, D. Sugianto, C. R. Bartz, and R. Tan, “Some clinical and epidemiological observations on biologically confirmed dengue haemorrhagic fever,” Paediatr Indones, vol. 30, no. 11-12, pp. 293–303, 1990.
[8]
P. Gurugama, P. Garg, J. Perera, A. Wijewickrama, and S. Seneviratne, “Dengue viral infections,” Indian Journal of Dermatology, vol. 55, no. 1, pp. 68–78, 2010.
[9]
N. C. Sukri, K. Laras, T. Wandra et al., “Transmission of epidemic dengue hemorrhagic fever in easternmost Indonesia,” American Journal of Tropical Medicine and Hygiene, vol. 68, no. 5, pp. 529–535, 2003.
[10]
I. Shah, G. C. Deshpande, and P. N. Tardeja, “Outbreak of dengue in Mumbai and predictive markers for dengue shock syndrome,” Journal of Tropical Pediatrics, vol. 50, no. 5, pp. 301–305, 2004.
[11]
S. Shivbalan, K. Anandnathan, S. Balasubramanian, M. Datta, and E. Amalraj, “Predictors of spontaneous bleeding in dengue,” Indian Journal of Pediatrics, vol. 71, no. 1, pp. 33–36, 2004.
[12]
V. Wiwanitkit, “Liver dysfunction in Dengue infection: an analysis of the previously published Thai cases,” JAMC, vol. 19, no. 1, pp. 10–12, 2007.
[13]
P. Futrakul, V. Poshyachinda, and C. Mitrakul, “Renal involvement. And reticulo endothelial system clearance in dengue hemorrhagic fever,” Journal of the Medical Association of Thailand, vol. 56, no. 1, pp. 33–39, 1973.
[14]
V. Boonpucknavig, N. Bhamarapravati, and S. Boonpucknavig, “Glomerular changes in dengue hemorrhagic fever,” Archives of Pathology and Laboratory Medicine, vol. 100, no. 4, pp. 206–212, 1976.
[15]
E. Q. Lima, F. S. Gorayeb, J. R. Zanon, M. L. Nogueira, H. J. Ramalho, and E. A. Burdmann, “Dengue haemorrhagic fever-induced acute kidney injury without hypotension, haemolysis or rhabdomyolysis,” Nephrology Dialysis Transplantation, vol. 22, no. 11, pp. 3322–3326, 2007.
[16]
M. C. Kuo, P. L. Lu, J. M. Chang et al., “Impact of renal failure on the outcome of dengue viral infection,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 5, pp. 1350–1356, 2008.
[17]
D. M. Salgado, J. M. Eltit, K. Mansfield et al., “Heart and skeletal muscle are targets of dengue virus infection,” Pediatric Infectious Disease Journal, vol. 29, no. 3, pp. 238–242, 2010.
[18]
V. Wiwanitkit, “Dengue myocarditis, rare but not fatal manifestation,” International Journal of Cardiology, vol. 112, no. 1, article 122, 2006.
[19]
R. Panpanich, P. Sornchai, and K. Kanjanaratanakorn, “Corticosteroids for treating dengue shock syndrome,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD003488, 2006.
[20]
S. A. M. Kularatne, C. Walathara, S. I. Mahindawansa et al., “Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study,” Postgraduate Medical Journal, vol. 85, no. 1008, pp. 525–529, 2009.
[21]
S. Rajapakse, “Dengue shock,” Journal of Emergencies, Trauma and Shock, vol. 4, no. 1, pp. 120–127, 2011.